第3回 UTOPIAシンポジウム

*Fumitaka Nagamura¹ (1. The Institute of Medical Science, The University of Tokyo (Japan))

*Michiko Koga^1,2, Hiroshi Yotsuyanagi^2,3 (1. The UTOPIA Center, The University of Tokyo (Japan), 2. IMSUT Hospital, The Institute of Medical Science, (Japan), 3. Japan Institute for Health Security (Japan))

*Yuji Tsunekawa¹, Ken Sugo¹, Hiromi Kinoh¹, Hiroshi Ueki², Seiya Yamayoshi², Takashi Okada¹ (1. The Division of Molecular and Medical Genetics, Institute of Medical Science The University of Tokyo (Japan), 2. Division of Virology, Institute of Medical Science The University of Tokyo (Japan))

*Koichi Watashi¹ (1. Department of Drug Development, National Institute of Infectious Diseases, Japan Institute for Health Security (Japan))

*Ryoma Nakao¹, Nozomu Obana², Kazuyoshi Kawahara³, Ryunosuke Tominaga¹, Masanori Toyofuku², Nobuhiko Nomura², Kimihiro Abe¹, Takehiro Yamaguchi¹, Yukihiro Akeda¹ (1. Department of Bacteriology I, National Institute of Infectious Diseases, JIHS (Japan), 2. University of Tsukuba (Japan), 3. Kanto Gakuin University (Japan))

*Takayuki Matsumura¹, Sayuri Nakahara², Daiki Oka², Tomohiro Takano¹, Kazutaka Terahara¹, Masanori Isogawa³, Yoshimasa Takahashi¹ (1. Research Center for Vaccine Development, National Institute of Infectious Diseases, Japan Institute for Health Security (Japan), 2. Meiji Seika Pharma Co., Ltd (Japan), 3. Department of Virology II, National Institute of Infectious Diseases, Japan Institute for Health Security (Japan))